Elicio Therapeutics, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 15/100
What the filing says
Elicio Therapeutics filed an 8-K on September 14, 2026, disclosing Item 5.08 (Shareholder Nominations pursuant to Exchange Act Rule 14a-11) and Item 8.01 (Other Events). The filing does not provide specific details about the nature, counterparties, dollar amounts, or concrete changes in the body text provided. Without access to the full exhibit content, the substance of these disclosures cannot be determined.
Why this rating
Routine 8-K filing with minimal disclosed detail; no quantified financial impact or operational change specified.
Extracted items
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.